Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer’s Disease
BARCELONA, SPAIN and CAMBRIDGE MA.
Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that the Company received approval of its Clinical Trial Application from the Spanish Drug Agency (AEMPS) to initiate a Phase I clinical trial for ORY-2001 for the treatment of Alzheimer's disease.